IgG hexamers initiate acute lung injury

Simon J. Cleary,Yurim Seo,Jennifer J. Tian,Nicholas Kwaan,David P. Bulkley,Arthur E. H. Bentlage,Gestur Vidarsson,Éric Boilard,Rolf Spirig,James C. Zimring,Mark R. Looney

DOI: https://doi.org/10.1101/2024.01.24.577129

2024-01-27

Abstract:Antibodies can initiate lung injury in a variety of disease states such as autoimmunity, transfusion reactions, or after organ transplantation, but the key factors determining in vivo pathogenicity of injury-inducing antibodies are unclear. A previously overlooked step in complement activation by IgG antibodies has been elucidated involving interactions between IgG Fc domains that enable assembly of IgG hexamers, which can optimally activate the complement cascade. Here, we tested the in vivo relevance of IgG hexamers in a complement-dependent alloantibody model of acute lung injury. We used three approaches to block alloantibody hexamerization (antibody carbamylation, the K439E Fc mutation, or treatment with domain B from Staphylococcal protein A), all of which reduced acute lung injury. Conversely, Fc mutations promoting spontaneous hexamerization made a harmful alloantibody into a more potent inducer of acute lung injury and rendered an innocuous alloantibody pathogenic. Treatment with a recombinant Fc hexamer ‘decoy’ therapeutic protected mice from lung injury, including in a model with transgenic human FCGR2A expression that exacerbated pathology. These results indicate a direct in vivo role of IgG hexamerization in initiating acute lung injury and the potential for therapeutics that inhibit or mimic hexamerization to treat antibody-mediated diseases.

Immunology

What problem does this paper attempt to address?

The paper aims to address the following issues:

1. **The role of IgG hexamers in acute lung injury**: The study investigates the phenomenon where IgG antibodies form hexamers through interactions in their Fc regions, triggering acute lung injury via the complement cascade. Specifically, the research focuses on the in vivo relevance of IgG hexamers in a complement-dependent xenogeneic antibody-mediated acute lung injury model.

2. **Effectiveness of interventions**: The paper tests several strategies to block xenogeneic antibody hexamerization (such as antibody carbonylation, Fc region mutations, and treatment with the B domain of Staphylococcus aureus protein A) and verifies whether these methods can reduce acute lung injury.

3. **Therapeutic potential**: The study also evaluates the effectiveness of a recombinant Fc hexamer "decoy" therapy, which can protect mice from acute lung injury, and explores the potential application of this therapy in human diseases.

Through these experiments, the researchers hope to elucidate the specific mechanisms of IgG hexamers in acute lung injury and propose new therapeutic strategies to inhibit or mimic the hexamerization process, thereby treating antibody-mediated diseases.